Bausch Health is being investigated by U.S. authorities in connection with marketing of four medicines used to treat different skin conditions, according to an internal document reviewed by STAT.
The Department of Justice sent a civil investigative demand last year to the company seeking information about various activities in which the medicines may have been promoted for uses not approved by regulators. The inquiry is focused on three drugs used to treat plaque psoriasis — Bryhali, Siliq, and Duobrii – and a fungal treatment called Jublia, the document stated.